Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia.

ABSTRACT:

Background

Despite international evidence demonstrating pre-emptive pharmacogenetics (PGx) screening is cost effective or cost saving in preventing serious or fatal toxicities, it is not routinely adopted in Australia. This study evaluated the cost effectiveness of PGx screening versus standard of care (SOC) among patients with cancer undergoing fluoropyrimidine-based treatment (FP) in Australia.

Methods

From the Australian healthcare perspective, we developed a cohort-based state transition model in TreeAge Pro 2024. The model used PACIFIC-PGx trial data for the PGx arm and literature-based inputs for the SOC arm. Patients transitioned between four health states (full-dose, reduced-dose, treatment termination or death) over two treatment cycles each corresponding to a stand

SUBMITTER: Glewis S 

PROVIDER: S-EPMC12669275 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature